Liposomal bupivacaine versus ropivacaine for surgical site infiltration in lumbar fusion: a prospective randomized controlled trial.

In 30 seconds

This prospective randomized controlled trial evaluated the efficacy of liposomal bupivacaine (LB) versus ropivacaine for surgical site infiltration in 202 patients undergoing lumbar fusion. The study found that LB significantly reduced cumulative opioid consumption within 72 hours, with a 22% relative reduction (43.0 mg vs. 58.0 mg, p < 0.001), while also lowering overall pain scores without increasing adverse events.

Key findings

• Cumulative opioid consumption was 43.0 mg in the LB group versus 58.0 mg in the R group.
• The LB group showed a 22% relative reduction in opioid use within 72 hours.
• Overall pain scores were lower in the LB group compared to the R group.
• No significant differences in rescue analgesia or adverse events were observed.

Why it matters

Effective pain management post-surgery is crucial for recovery and reducing opioid reliance. This study suggests that liposomal bupivacaine may offer a beneficial alternative for pain control in lumbar fusion surgeries, potentially improving patient outcomes.